» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

COG-AALL06N1

Trial

Clinical Trial Title

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Trial Status

Closed to Enrollment

Start Date

April 16, 2007

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Neurocognitive Function (ALL)

Description

A Study of Neurocognitive Function in Children Treated for Acute Lymphoblastic Leukemia (ALL)

Eligibility Criteria

Patient must have been >1 year and <18 years of age at the time diagnosed as having ALL

Patient must be enrolled on AALL0434 (Cohort #1 only) or AALL0232 (Cohort #1 and #2) and must have received either high dose methotrexate or escalating dose methotrexate during interim maintenance

Eligibility time period is 8-24 months post completion of AALL0232 protocol treatment

Notes

https://clinicaltrials.gov/ct2/show/NCT00437060

Study status is:
Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program

Phone

(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:04 AM